Jacobio Pharmaceuticals

1167 · HKEX

Public Market Listing

1167HKEX

HKEX primary exchange listing

Live quotes, historical charts, and market capitalization for Jacobio Pharmaceuticals are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(4 total)
4Total Assets
0Approved
2Phase 3 / Filed
2Phase 1–2 / Early
3Diseases
Quick filter:
Showing 4 of 4 assets
Target & Modality
Phase 3
KRAS G12CSmall molecule
Non-Small Cell Lung Cancer
Phase 3
SHP2Small molecule
Non-Small Cell Lung Cancer
Phase 2
BET bromodomain proteins (e.g. BRD4)Small molecule
Non-Small Cell Lung CancerRheumatoid ArthritisMyelofibrosis
Phase 1/2
KRAS MutantSmall molecule
Non-Small Cell Lung Cancer

Upcoming events

(9 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (2)
December 2026 (2)
JAB-23E73Phase 1/2Advanced Solid Tumor
Est. primary completion 2026-12-31 · NCT06959615 · CT.gov ↗
What to watch
GlecirasibPhase 2KRAS P.G12C, Pancreatic Cancer, Solid Tumor
Est. primary completion 2026-12-31 · NCT06008288 · CT.gov ↗
What to watch
2027 (3)
March 2027 (1)
Glecirasib + SitneprotafibPhase 1/2KRAS P.G12C, Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Carcinoma
Est. primary completion 2027-03 · NCT05288205 · CT.gov ↗
What to watch
June 2027 (1)
JAB-8263Phase 2Rheumatoid Arthritis (RA)
Est. primary completion 2027-06-30 · NCT07684157 · CT.gov ↗
What to watch
August 2027 (1)
GlecirasibPhase 1/2Non-small Cell Lung Cancer
Est. primary completion 2027-08 · NCT05276726 · CT.gov ↗
What to watch
2028 (2)
January 2028 (1)
JAB-8263Phase 1/2NSCLC, SCLC, CRPC, ESCC, Ovarian Carcinoma, AML, MF, Malignant Tumor
Est. primary completion 2028-01 · NCT04686682 · CT.gov ↗
What to watch
November 2028 (1)
JAB-23E73Phase 1/2Advanced Solid Tumors
Est. primary completion 2028-11 · NCT06973564 · CT.gov ↗
What to watch
2029 (2)
September 2029 (1)
Glecirasib + SitneprotafibPhase 3Advanced Non-squamous Non-small-cell Lung Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer
Est. primary completion 2029-09-30 · NCT06416410 · CT.gov ↗
What to watch
December 2029 (1)
JAB-23E73Phase 1/2Metastatic Pancreatic Ductal Adenocarcinoma
Est. primary completion 2029-12-31 · NCT07640295 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Quarterly & interim (1)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-H1$6.3M$13M$149M$8.1Mreport ↗

Annual history (1 year)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$22M$46M$199M—report ↗

Jacobio Pharmaceuticals reported 2024 annual revenue of $22.27M, R&D spend of $45.93M, and cash and equivalents of $198.68M. Net income or loss was not disclosed in the provided figures, and no year-over-year comparison was available.

The company highlighted key clinical progress, including the submission of an NDA for its KRAS G12C inhibitor glecirasib in second-line and above non-small cell lung cancer, with expected approval in the first half of 2025, and an August 2024 licensing agreement with Allist covering China rights to glecirasib and the SHP2 inhibitor sitneprotafib. Additional updates included ongoing Phase III trials, IND approvals for early-stage candidates JAB-23E73 and JAB-30355, and completed dose escalation for JAB-8263.